Acelyrin’s IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO

Acelyrin said Monday that its lead drug izokibep failed to meet the primary endpoint in a Phase IIb/III trial in patients with hidradenitis suppurativa — a chronic inflammatory condition that causes painful nodules and abscesses to form under the skin.

It’s the Los Angeles biotech’s first big clinical readout since…
Click here to view original post